Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Makya stands out as the pioneering user-centric SaaS platform dedicated to AI-enhanced de novo drug design, particularly emphasizing Multi-Parametric Optimization (MPO). This innovative tool empowers users to create novel and easily synthesize compounds based on a multi-objective framework, achieving unprecedented levels of speed, efficiency, and variety. Makya incorporates a range of generative algorithms tailored to various stages of drug development, from hit discovery to lead optimization; it includes a fine-tuning generator for pinpointing ideal solutions within your specified chemical landscape, a novelty generator designed to explore fresh concepts for re-scaffolding and hit discovery, and a forward generator to create a targeted library of compounds that can be readily synthesized from commercially available starting materials. The recently introduced Makya 3D module significantly improves both the user interface and the scientific capabilities of the platform. With a comprehensive array of 3D modeling functionalities available for both ligand-based and structure-based approaches, Makya 3D allows for the calculation of 3D scores, which can be seamlessly utilized to guide compound generation within the platform. This integration not only enhances the design process but also offers researchers deeper insights into their molecular designs.

Description

Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

Amazon Web Services (AWS)
Google Cloud Platform
Microsoft Azure
Python

Integrations

Amazon Web Services (AWS)
Google Cloud Platform
Microsoft Azure
Python

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Iktos

Country

France

Website

iktos.ai/makya/

Vendor Details

Company Name

Recursion

Country

United States

Website

www.recursion.com

Product Features

Alternatives

Alternatives

SILCS Reviews

SILCS

SilcsBio
AIDDISON Reviews

AIDDISON

Merck KGaA